Omadacycline (DrugBank: Omadacycline)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 299 | 嚢胞性線維症 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04460586 (ClinicalTrials.gov) | September 1, 2020 | 1/7/2020 | Pharmacokinetics of Omadacycline in Cystic Fibrosis | Pharmacokinetics of Omadacycline in Patients With Cystic Fibrosis | Cystic Fibrosis | Drug: Omadacycline Injection [Nuzyra];Drug: Omadacycline Oral Tablet [Nuzyra] | Paul Beringer | Paratek Pharmaceuticals Inc | Not yet recruiting | 18 Years | N/A | All | 12 | Phase 4 | United States |